Clinical trials: BCG
IPV
ID Administration of fIPV Using Intradermal Adapters vs. BCG Syringe
The investigators will assess the usability and immune response following fractional dose inactivated polio virus vaccine (fIPV) administration with two novel intradermal adapters (ID adapter by West Pharmaceutical services Inc.
- Trial name
- ID-ADAP (NCT02769923)
- Testing
- Westpharma ID adapter, Star ID syringe, BCG NS
- Volunteers
- 450 people
- Sponsor
- Aga Khan University
Tuberculosis
Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa
Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis (TB) for residents in endemic areas…
- Trial name
- NCT01479972
- Testing
- VPM1002, BCG
- Where
- South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Tuberculosis
A Study of MVA85A in Healthy Children and Infants
This study is designed to evaluate the safety of the TB vaccine MVA85A in healthy children and infants in South Africa. A single vaccination with MVA85A has been shown to be safe and highly immunogenic in a wide range of subjects…
- Trial name
- NCT00679159
- Testing
- MVA85A, Prevenar
- Where
- South Africa
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Oxford
LTBI, BCG Vaccination Reaction
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
TB-reactive immune cells will be tested in a multiparametric flow cytometry to distinguish an immune response for antigens of Mycobacterium spp. in TB disease/latent infection or a reaction after BCG vaccine.
- Conditions
- LTBI, BCG Vaccination Reaction, TB
- Trial name
- NCT04673227
- Testing
- Blood draw
- Where
- 2 sites in Czechia
- Volunteers
- 120 people
- Sponsor
- Thomayer University Hospital
Vaccine Preventable Disease, Measles
Measles and BCG Vaccines for Mother and Child
In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other…
- Conditions
- Vaccine Preventable Disease, Measles, Mother-Infant Interaction, BCG Vaccination Reaction
- Trial name
- MATVAC (NCT04899765)
- Testing
- BCG vaccine, Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Infant Mortality, BCG
Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?
Bacillus Calmette-Guérin (BCG) vaccination is recommended at birth to protect against tuberculosis (TB) in countries with high TB burden. BCG is supplied in multidose vials with limited durability after reconstitution.
- Trial name
- CS-BCG (NCT04658680)
- Testing
- BCG vaccination at first health facility contact
- Where
- Guinea-Bissau
- Volunteers
- 22,800 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
BCG Infection, Reaction - Vaccine
A Study of the Interaction Between BCG And MenC Immunisation: BAM
The Bacille Calmette-Guérin (BCG) vaccine is the only vaccine licenced to prevent tuberculosis (TB). The stimulus it gives to the immune system allows it to respond more effectively to a subsequent infection with TB.
- Conditions
- BCG Infection, Reaction - Vaccine, Immune Response
- Trial name
- BAM (NCT02002156)
- Testing
- BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Innate Immune Response
A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study
Neonatal morbidity and mortality from infectious diseases is of global concern. Childhood disease-specific immunisation is irrefutably linked to the decline in deaths from these targeted infections over the last century.
- Trial name
- ELVIS (NCT02444611)
- Testing
- BCG Vaccine, Hepatitis B Vaccine
- Where
- Australia
- Volunteers
- 185 people
- Sponsor
- Murdoch Childrens Research Institute
COVID-19, BCG Vaccination
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?
There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is…
- Trial name
- NCT04347876
- Testing
- Tuberculin test
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Tuberculosis
Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe
The study is designed to test the hypothesis that BCG administration via jet injector will produce a comparable immune response and that there will be no significant differences in safety or reactogenicity between BCG…
- Trial name
- NCT01742364
- Testing
- Bioject ID Pen, Needle and syringe
- Where
- South Africa
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- PATH
Tuberculosis
Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon
Filarial nematodes modulate the host immune response to promote regulatory and T helper type 2 immune responses, which were shown to influence concomitant infections.
- Trial name
- MAP-TB (NCT04547738)
- Testing
- TB treatment according to national guidelines
- Where
- Cameroon
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Early Neonatal Mortality
A Randomized Trial of Providing BCG Vaccination Immediately
Recent studies show that BCG vaccination reduces neonatal mortality by more than 40%. This effect cannot be explained by prevention of tuberculosis, which is very rare among infants.
- Trial name
- NCT01989026
- Testing
- BCG
- Where
- Guinea-Bissau
- Volunteers
- 3,361 people
- Sponsor
- Bandim Health Project
Tuberculosis Infection, Tuberculosis
BCG Revaccination in Children and Adolescents
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection.
- Trial name
- BRiC (NCT05330884)
- Testing
- BCG vaccine, Oral Chemoprophylaxis
- Where
- India
- Volunteers
- 9,200 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Non Muscle Invasive Bladder Cancer
Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)
The goal of this clinical trial is to compare the efficacy and safety of two Bacillus Calmette-Guérin (BCG) substrains (RIVM and Russian) in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)…
- Trial name
- NCT06767982
- Testing
- Bacillus Calmette-Guerin (BCG)
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Ankara University
Infant Morbidity, Infant Mortality
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Studies in low-income countries show that vaccines can have important non-specific effects on other infections. Live BCG vaccine can train the immune system and reduce susceptibility to unrelated infections.
- Conditions
- Infant Morbidity, Infant Mortality, Non-Specific Effects of Vaccines, BCG
- Trial name
- BCG2-DTP3 (NCT07005726)
- Testing
- BCG Vaccine
- Where
- Guinea-Bissau
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Non Specific Effects of Vaccine, Bacillus-Calmette-Guerin
Low Birth Weight Follow-up
The Randomized Control Trail included 4,172 low-birth weight children between February 2008 and September 2013 in Bissau. The children who were included in the RCT and who are living in the Bandim Health Project study area will…
- Conditions
- Non Specific Effects of Vaccine, Bacillus-Calmette-Guerin, Low Birth Weight, Maternal Immunisation
- Trial name
- NCT03020147
- Where
- Guinea-Bissau
- Volunteers
- 1,258 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Mycobacterium Tuberculosis Infection
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation)…
- Trial name
- VPM1002 (NCT04351685)
- Testing
- VPM1002, BCG SII
- Where
- 12 sites in Gabon, Kenya and 3 more
- Volunteers
- 6,940 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Asthma, Eczema
Bacille Calmette-Guérin (BCG) Vaccine and Atopy
The prevalence of asthma and allergic diseases is increasing worldwide. Infections and vaccinations in childhood may have an impact on the subsequent development of asthma and allergy.
- Conditions
- Asthma, Eczema, Food Hypersensitivity
- Trial name
- NCT01420705
- Where
- Guinea-Bissau
- Volunteers
- 487 people
- Sponsor
- Bandim Health Project
Malaria
Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria
BCG vaccine is given at or shortly after birth in many developing countries to prevent tuberculosis. In Guinea Bissau, it has been shown that its protective effect against death is greater than would be expected from its effect…
- Trial name
- NCT00131794
- Testing
- BCG
- Where
- Guinea-Bissau
- Volunteers
- 1,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Tuberculosis
Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection
The purpose of this study is to demonstrate the efficacy of Bacille Calmette Guerin (BCG) revaccination against sustained Mycobacterium tuberculosis infection versus placebo in previously BCG vaccinated QuantiFERON®-TB Gold Plus…
- Trial name
- NCT04152161
- Testing
- BCG vaccine SSI
- Where
- 5 sites in South Africa
- Volunteers
- 1,836 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute